Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
A.W. Mech
Publikováno v:
European Psychiatry. 41:S730-S730
IntroductionVitamin D has been shown to be crucial in the regulation of dopamine and its relationship to major depressive disorder.A five-year pre-interventional study of 25 hydroxy vitamin D levels in patients with major depressive disorder found va
Autor:
Emmanuelle Weiller, Mette Gislum, Aleksandar Skuban, Catherine Weiss, Stephen R. Marder, Mika Juhani Hakala
Publikováno v:
European Psychiatry. 33:S99-S99
IntroductionBrexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.ObjectivesEvaluating the efficac
Autor:
Laia Grau-López, Carlos Roncero, Sergi Valero, J. Alvarós, Begoña Gonzalvo, M. Corominas, Constanza Daigre, A. Egido, Miquel Casas, S. Gómez-Baeza, X. Castells, E. Ros-Cucurrull
Publikováno v:
European Psychiatry. 29:1
Purpose The aim of this study was to test the efficacy of caffeine with or without biperiden in the treatment of cocaine dependent patients. Methods A randomized, double blind, placebo-controlled clinical trial has been carried out in an inpatient re
Publikováno v:
European Psychiatry. 23:S259-S260
Aim:To evaluate the efficacy and tolerability of once-daily quetiapine XR (extended release) monotherapy in patients with MDD (unipolar depression) compared with placebo.Methods:8-week (6-week active treatment, randomised phase; 2-week post-treatment
Publikováno v:
European Psychiatry. 28:1
Introduction We describe the efficacy and safety of as-needed use of nalmefene in the subgroup of patients with a high drinking risk level (DRL; men:>60g/day; women:>40g/day); i.e. a group of patients with a great unmet medical need for treatment. Ob
Publikováno v:
European Psychiatry. 28:1
Introduction In the phase 3 programme on nalmefene for reduction of alcohol consumption in alcohol dependent patients, an as-needed dosing regimen was used. Patients were instructed to take one tablet on each day they perceived a risk of drinking alc
Publikováno v:
European Psychiatry. 28:1
Introduction We describe the efficacy and safety of as-needed use of nalmefene in the subgroup of patients with a high drinking risk level (DRL; men:>60g/day; women:>40g/day); i.e. a group of patients with a great unmet medical need for. Objectives T
Publikováno v:
European Psychiatry. 27:1
Introduction Current treatments for alcohol dependence, aiming to keep patients abstinent, have shown limited treatment and success rates. Reduction of alcohol consumption is increasingly recognised as a valid and needed option that should be an inte
Autor:
O. De Vita, Luigi Guerriero, Daniela Tedeschi, Giovanni Martinotti, Riccardo Guglielmo, Luigi Janiri, M. Di Nicola, R. De Filippis
Publikováno v:
European Psychiatry. 25:1-1
IntroductionTopiramate (up to 300 mg per day) is more efficacious than placebo as an adjunct to standardised medication compliance management in treatment of alcohol dependence. However, adverse events can limit its use in different clinical situatio
Autor:
Yili Lu, David J. Goldstein, Craig H. Mallinckrodt, Curtis Wiltse, Mark A. Demitrack, Michael J. Detke, István Bitter
Publikováno v:
European Psychiatry. 17:98